MZT2B and non-small cell lung carcinoma: The identification of MZT2B as a consistently upregulated oncogenic driver in NSCLC carries profound clinical implications and emerges as a vulnerability that could be exploited through targeted inhibitors, perhaps in combination with standard NSCLC therapies, including immune checkpoint inhibitors.